Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein

Antibodies elicited by protein therapeutics can cause serious side effects in humans. We studied immunogenicity of a recombinant fusion protein (FPX) consisting of two identical, biologically active, peptides attached to human Fc fragment. EpiMatrix, an in silico epitope-mapping tool, predicted prom...

Description complète

Détails bibliographiques

Publié dans:	Clinical immunology (Orlando, Fla.). - 1999. - 124(2007), 1 vom: 01. Juli, Seite 26-32
Auteur principal:	Koren, E (Auteur)
Autres auteurs:	De Groot, A S, Jawa, V, Beck, K D, Boone, T, Rivera, D, Li, L, Mytych, D, Koscec, M, Weeraratne, D, Swanson, S, Martin, W
Format:	Article
Langue:	English
Publié:	2007
Accès à la collection:	Clinical immunology (Orlando, Fla.)
Sujets:	Comparative Study Evaluation Study Journal Article Validation Study Epitopes, T-Lymphocyte Immunodominant Epitopes Recombinant Fusion Proteins